After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (VKTX 10.60%) is now doubtlessly on many investors' radars. Soon enough, the biotech will likely try to launch a new weight loss medication capable of rivaling Novo Nordisk's (NVO 3.72%) blockbuster obesity drug, Wegovy. That means people who feel that they learned about Novo Nordisk's rapidly growing obesity care segment too late to see any upside from an investment now have anot ...

Leave Oprah alone.Yes, Oprah Winfrey is in the news again — in this case, for her decision to sell her stake in WW International WW, +8.33% (formerly known as WeightWatchers) and leave the company’s board. The decision came after Winfrey announced, to considerable backlash, that she was taking a weight-loss drug to help her in her longtime battle to lose some pounds and keep them off, in addition to hiking, drinking plenty of water and other methods.The company’s stock fell in the aftermath of the news. At ...

Novo Nordisk's (NVO 3.72%) position as a hot healthcare stock got a boost from an analyst as the trading week came to a close. On a significant price target boost, the Danish pharmaceutical company's share price closed the day almost 4% higher. That was more than good enough to outpace the bellwether S&P 500 index, which rose by a relatively light 0.8%.An analyst raised his price target at a double-digit rateThe analyst giving Novo Nordisk that nice shot in the arm was Morgan Stanley's Mark Purcell. Well be ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Developed alongsid ...

NurPhoto/NurPhoto via Getty Images In 2023, it was the Yahoo Finance ‘Company of the Year’; Lars Fruergaard Jørgensen was the FT ‘CEO of the Year’; its stock rose ~53% to become the largest company in Europe by market capitalization; and the Danish government had to provide its official figures adjusted to exclude its impact. What a year Novo Nordisk (NVO) has had. This was driven by its novel GLP-1 therapeutics, Wegovy and Ozempic, which have become household names attracting a buzz deafened only by th ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks S ...

Novo Nordisk (NVO 1.86%), a Danish pharmaceutical company, is the developer of Ozempic, which is often referred to as a weight-loss drug. But there is actually a nuance, albeit an important one, to discuss.Ozempic is a glucagon-like peptide-1 (GLP-1) agonist that uses semaglutide and is typically prescribed for patients with diabetes. While losing weight can be affiliated with taking it, the drug itself is not approved by the Food and Drug Administration (FDA) for that specific use.Nevertheless, demand for ...

Novo Nordisk CEO Lars Fruergaard Jorgensen has been fielding calls from food company chief executives who have questions about the company's diabetes and weight-loss-related drugs. "They are scared about it," Jorgensen told Bloomberg. The company confirmed to FOX Business he did not name names. However, it is no surprise that these drugs – Ozempic and Wegovy – which are the same medication but have different FDA-approved intended uses and are known to suppress appetites and change food preferences – are cat ...

anilakkus Investment Thesis In this article, I explore Novo Nordisk (NVO). I provide some very relevant information regarding where the company stands with product and the outlook as we begin the 2024 year. There have been major updates with Wegovy and the company’s weight loss drug market, so we will dive into each of them. Despite skepticism about the sustainability of this sector's growth, I maintain a bullish stance. The increasing demand and improved accessibility of GLP-1 drugs along with the very ...

Alexander Spatari/Moment via Getty Images Who would have though Denmark would have been one of the biggest beneficiaries of weight loss drugs? With a weighting of 23% in the iShares MSCI Denmark ETF (BATS:EDEN), it's no wonder that the fund has done well. Of course, this ETF is more than just a single stock, and it's worth exploring the investment case here. EDEN is a fund designed to closely track the investment results of a broad-based index composed of Danish equities. The ETF provides its investors ...